Gene-Editing and RNA Interference in Treating Hepatitis B: A Review

Author:

Kasianchuk Nadiia1ORCID,Dobrowolska Krystyna2ORCID,Harkava Sofiia3ORCID,Bretcan Andreea4,Zarębska-Michaluk Dorota5ORCID,Jaroszewicz Jerzy6,Flisiak Robert7ORCID,Rzymski Piotr8ORCID

Affiliation:

1. Faculty of Biology, Adam Mickiewicz University in Poznań, 61-614 Poznań, Poland

2. Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland

3. Junior Academy of Sciences of Ukraine, Regional Branch in Dnipro, 49000 Dnipro, Ukraine

4. National College “Ienăchiță Văcărescu”, 130016 Târgoviște, Romania

5. Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland

6. Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, Poland

7. Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, Poland

8. Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Poznań, Poland

Abstract

The hepatitis B virus (HBV) continues to cause substantial health and economic burdens, and its target of elimination may not be reached in 2030 without further efforts in diagnostics, non-pharmaceutical prevention measures, vaccination, and treatment. Current therapeutic options in chronic HBV, based on interferons and/or nucleos(t)ide analogs, suppress the virus replication but do not eliminate the pathogen and suffer from several constraints. This paper reviews the progress on biotechnological approaches in functional and definitive HBV treatments, including gene-editing tools, i.e., zinc-finger proteins, transcription activator-like effector nucleases, and CRISPR/Cas9, as well as therapeutics based on RNA interference. The advantages and challenges of these approaches are also discussed. Although the safety and efficacy of gene-editing tools in HBV therapies are yet to be demonstrated, they show promise for the revitalization of a much-needed advance in the field and offer viral eradication. Particular hopes are related to CRISPR/Cas9; however, therapeutics employing this system are yet to enter the clinical testing phases. In contrast, a number of candidates based on RNA interference, intending to confer a functional cure, have already been introduced to human studies. However, larger and longer trials are required to assess their efficacy and safety. Considering that prevention is always superior to treatment, it is essential to pursue global efforts in HBV vaccination.

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference201 articles.

1. Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection;Tsai;Gastroenterol. Hepatol.,2021

2. Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery;Zhao;Innovation,2020

3. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients;Huang;Hepatology,2021

4. Global Prevalence, Cascade of Care, and Prophylaxis Coverage of Hepatitis B in 2022: A Modelling Study;Gamkrelidze;Lancet Gastroenterol. Hepatol.,2023

5. WHO (2023, May 14). Hepatitis B. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3